ABVC Biopharma (ABVC) Stock Price

ABVC Biopharma Price

NYSE·CLOSED
0.91
​
Market closed

Revenue has compounded at 16.8% per year over the past 19 years to 795,950.00 USD. ABVC Biopharma's net margin stands at -993.6%, up from -3,608.5% several years earlier. Analysts set a median price target of 2.06 USD, implying 126.4% above the current price. Of 6 analysts, 0 rate the stock a buy — an overall Sell consensus.

ABVC Biopharma stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ABVC Biopharma business model & stock analysis

American BriVision (Holding) Corp. is a clinical stage biopharmaceutical company focused on developing new drugs and medical devices. It utilizes licensed technology to enhance pre-existing pharmaceutical products for cancer treatments and other diseases, with a focus on identifying responsive patients. The company operates through five compounds licensed from BioLite Inc.: ABV-1501, ABV-1502, ABV-1503, ABV-1504, and ABV-1505. As of September 30, 2016, the company had not generated any revenues from its operations. The firm's revenue model relies on the development and commercialization of its licensed compounds. It partners with BioLite Inc. for the technology and compounds, which it aims to enhance and commercialize in various markets. The company targets cancer indications and other diseases for its pharmaceutical products, seeking to identify patients who may respond to these treatments. The clinical-stage nature of its operations means it is still in the research and development phase without current revenue streams. American BriVision (Holding) Corp. is headquartered in Fremont, California, and employs 34 full-time employees. It went public via IPO on November 9, 2004. The company's focus on enhancing pre-existing drugs through licensed technology positions it for future revenue generation once its compounds reach commercialization. However, as of the latest data, it has not yet generated any revenue from its operations.

Frequently asked questions about ABVC Biopharma

Analysts currently set an average price target of 2.06 USD for the ABVC Biopharma stock (median: 2.06 USD), implying +126.4 % versus the latest price. The consensus is based on 6 analyst ratings.

6 analysts currently rate the ABVC Biopharma stock: 0 recommend buying, 3 holding and 3 selling.

Converted at the current exchange rate, the ABVC Biopharma share trades at 0.83 EUR (0.91 USD).

The revenue cannot currently be calculated for ABVC Biopharma.

The profit cannot currently be calculated for ABVC Biopharma.

The P/E ratio cannot be calculated for ABVC Biopharma at the moment.

The P/S cannot be calculated for ABVC Biopharma currently.

The Eulerpool Quality Score for ABVC Biopharma is 4/10.

The ISIN of ABVC Biopharma is US00091F3047. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of ABVC Biopharma is ABVC. The ticker symbol is used to trade ABVC Biopharma shares on the stock exchange.

Fair ValueTerminal
0.77 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue per Employee
26,531.67 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website
Currency
USD
Initial public offering
Nov 9, 2004
ISIN
US00091F3047
Cusip
024733206
Sedol
BK5XLV1
Market capitalization
10.62 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
0.96
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-54.23 %
Last updated Nov 16, 2026, 3:46 AM

ABVC Biopharma Peer Group